MB has shown potential for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS), which is a genetic, premature aging disorder caused by a C to T de novo point mutation on exon 11 of the LMNA gene [93]. This evidence concerns the gene LMNA and Hutchinson-Gilford progeria syndrome.